Роль микроРНК в диагностике рака почки
https://doi.org/10.18705/2782-3806-2023-3-5-46-59
EDN: BAXAQW
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Полный текст:
Аннотация
В обзоре проводится анализ литературных данных о роли циркулирующих микроРНК (миРНК) при различных гистологических типах рака почки у человека. Приведены основные сведения о механизмах биогенеза данных молекул, рассмотрена их регуляторная роль. Особое внимание уделяется перспективе использования миРНК в качестве диагностических и прогностических биомаркеров рака почки с учетом противоречивых данных, выявленных в различных исследованиях.
Ключевые слова
биомаркеры,
диагностика,
карциногенез,
микроРНК,
прогностика,
рак почки,
циркулирующие миРНК,
экзосомы
При поддержке: Работа поддержана ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России.
Об авторах
А. Б. Бондаренко
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
Бондаренко Андрей Борисович, младший научный сотрудник НИЛ инфекционных патогенов и биомолекулярных наноструктур НМИЦ им. В. А. Алмазова; старший преподаватель кафедры медицинской биологии СПбГПМУ,
г. Санкт-Петербург.
А. Р. Князева
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
Князева Александра Романовна, лаборант-исследователь НИЛ нейрогенеза и нейродегенеративных заболеваний НМИЦ им. В. А. Алмазова; старший лаборант кафедры медицинской биологии СПбГПМУ,
г. Санкт-Петербург.
Ю. В. Чебуркин
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации
Россия
Россия
Чебуркин Юрий Владимирович, к.м.н., заведующий НИЛ инфекционных патогенов и биомолекулярных наноструктур, старший научный сотрудник НИО микроциркуляции и метаболизма миокарда,
г. Санкт-Петербург.
Список литературы
1. Чебуркин Ю.В., Князева Т.Г., Петер Ш. и др. Молекулярный портрет карцином почки человека, полученный на основе экспрессии протеин-тирозин-киназ и тирозин-фосфатаз, контролирующих передачу регуляторных сигналов в клетках. Молекулярная биология. 2002; 36(3): 480-490]. https://doi.org/10.1023/A:1016059313254.
2. Князев Ю.П., Чебуркин Ю.В., Спикерманн К. и др. Профили экспрессии протеинкиназ и фосфатаз, полученные с помощью упорядоченных наборов кДНК (cDNA Arrays): молекулярный портрет рака предстательной железы. Молекулярная биология. 2003; 37(1): 97-111]. https://doi.org/10.1023/A:1022341015018.
3. Tran DH, Satou K, Ho TB. Finding microRNA regulatory modules in human genome using rule induction. BMC Bioinformatics. 2008; 12;9 (Suppl 12):S5. https://doi.org/10.1186/1471-2105-9-S12-S5.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9:669-676. https://doi.org/10.1038/nm0603-669.
5. Rodriguez A, Griffiths-Jones S, Ashurst JL, et al. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004; 14: 1902-1910. https://doi.org/10.1101/gr.2722704.
6. Bartel DP. Metazoan MicroRNAs. Cell. 2018; 173: 20-51. https://doi.org/10.1016/j.cell.2018.03.006.
7. Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat. Rev. Mol. Cell Biol. 2019; 20: 21-37. https://doi.org/10.1038/s41580-018-0045-7.
8. Bortoletto AS and Parchem RJ. KRAS Hijacks the miRNA Regulatory Pathway in Cancer. Cancer Research. 2023; 83(10): 1563-1572. https://doi.org/10.1158/0008-5472.CAN-23-0296.
9. Matsuyama H, Suzuki HI. Systems and Synthetic microRNA Biology: From Biogenesis to Disease Pathogenesis. Int. J. Mol. Sci. 2019; 21(1):132. https://doi.org/10.3390/ijms21010132.
10. Komatsu S, Kitai H, Suzuki HI. Network regulation of microRNA biogenesis and target interaction. Cells. 2023; 12(2): 306. https://doi.org/10.3390/cells12020306.
11. Corcoran DL, Pandit KV, Gordon B, et al. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PloS One. 2009; 4(4): e5279. https://doi.org/10.1371/journal.pone.0005279.
12. Vorozheykin PS, Titov II. Erratum to: How animal miRNAs structure influences their biogenesis. Russian Journal of Genetics. 2020; 56: 1012-1024. https://doi.org/10.1134/S1022795420220019.
13. Веряскина Ю.А., Титов С.Е., Ковынев И.Б. и др. МикроРНК при миелодиспластическом синдроме. Acta Naturae. 2021; 13(2): 4-15]. https://doi.org/10.32607/actanaturae.11209.
14. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004; 23: 4051-4060. https://doi.org/10.1038/sj.emboj.7600385.
15. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol. 2006; 13: 1097-1101. https://doi.org/10.1038/nsmb1167.
16. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proceedings of the National Academy of Sciences. 2007; 104(45): 17719-17724. https://doi.org/10.1073/pnas.0703890104.
17. Suzuki HI, Young RA, Sharp PA. Super-enhancermediated RNA processing revealed by integrative microRNA network analysis. Cell. 2017; 168(6): 1000-1014. https://doi.org/10.1016/j.cell.2017.02.015.
18. O’Brien J, Hayder H, Zayed Y, et al. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. 2018; 9(402): 1-12. https://doi.org/10.3389/fendo.2018.00402.
19. Starega-Roslan J, Galka-Marciniak P, Krzyzosiak WJ. Nucleotide sequence of miRNA precursor contributes to cleavage site selection by Dicer. Nucleic acids research. 2015; 43(22): 10939-10951. https://doi.org/10.1093/nar/gkv968.
20. Butkyte S, Ciupas L, Jakubauskiene E, et al. Splicing-dependent expression of microRNAs of mirtron origin in human digestive and excretory system cancer cells. Clinical epigenetics. 2016; 8(1): 1-11. https://doi.org/10.1186/s13148-016-0200-y.
21. Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes & development. 2003; 17(24): 3011-3016. https://doi.org/10.1101/gad.1158803.
22. Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science; 2004; 303(5654): 95-98. https://doi.org/10.1126/science.1090599.
23. Wang X, Xu X, Ma Z, et al. Dynamic mechanisms for pre-miRNA binding and export by Exportin-5. RNA. 2011; 17(8): 1511-1528. https://doi.org/10.1261/rna.2732611.
24. Melo SA, Moutinho C, Ropero S, et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer cell. 2010; 18(4): 303-315. https://doi.org/10.1016/j.ccr.2010.09.007.
25. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005; 436: 740-4. https://doi.org/10.1038/nature03868.
26. Kok KH, Ng MH, Ching YP, et al. Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA. J Biol Chem. 2007; 282: 17649-57. https://doi.org/10.1074/jbc.M611768200.
27. Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer science. 2010; 101(11): 2309-2315. https://doi.org/10.1111/j.1349-7006.2010.01683.x.
28. MacFarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Current genomics. 2010; 11(7): 537-561. https://doi.org/10.2174/138920210793175895.
29. Mückstein U, Tafer H, Hackermüller J, et al. Thermodynamics of RNA-RNA binding. Bioinformatics. 2006; 22(10): 1177-1182. https://doi.org/10.1093/bioinformatics/btl024.
30. Deng Y, Wang CC, Choy KW, et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene. 2014; 538(2): 217-227. https://doi.org/10.1016/j.gene.2013.12.019.
31. Gu S, Kay MA. How do miRNAs mediate translational repression? Silence. 2010; 1(11): 1-5. https://doi.org/10.1186/1758-907X-1-11.
32. Wilczynska A, Bushell M. The complexity of miRNA-mediated repression. Cell Death & Differentiation. 2015; 22(1): 22-33. https://doi.org/10.1038/cdd.2014.112.
33. Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature. 2009; 460(7254): 529-533. https://doi.org/10.1038/nature08199.
34. Liang B, Zhao J, Wang X. A three-microRNA signature as a diagnostic and prognostic marker in clear cell renal cancer: An In Silico analysis. PloS One. 2017; 12(6): e0180660. https://doi.org/10.1371/journal.pone.0180660.
35. Mytsyk Y, Dosenko V, Borys Y, et al. MicroRNA15a expression measured in urine samples as a potential biomarker of renal cell carcinoma. Int Urol Nephrol. 2018; 50(5): 851-859. https://doi.org/10.1007/s11255-018-1841-x.
36. Nofech-Mozes R, Khella HWZ, Scorilas A, et al. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Med. 2016; 5(4): 656-664. https://doi.org/10.1002/cam4.631.
37. Quan J, Pan X, Li Y, et al. MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC. BioMed Pharmacother. 2019; 110: 656-666. https://doi.org/10.1016/j.biopha.2018.11.065.
38. Cao J, Liu J, Xu R, et al. MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells. Mol Med Rep. 2016; 13(1): 75-82. https://doi.org/10.3892/mmr.2015.4568.
39. Ching T, Zhu X, Garmire LX. Cox-nnet: an artificial neural network method for prognosis prediction of high-throughput omics data. PloS Comput Biol. 2018; 14(4): e1006076. https://doi.org/10.1371/journal.pcbi.1006076.
40. Ge YZ, Xu LW, Zhou CC, et al. A BAP1 Mutationspecific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wildtype BAP1. Int J Cancer. 2017; 8(13): 2643-52. https://doi.org/10.7150/ jca.20234.
41. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3): 499-505. https://doi.org/10.1097/SLA.0b013e3181cc939f.
42. Hamam R, Hamam D, Alsaleh KA, et al. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis. 2017; 8(9): e3045. https://doi.org/10.1038/cddis.2017.440.
43. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011; 6(3), e17745. https://doi.org/10.1371/journal.pone.0017745.
44. Imaoka H, Toiyama Y, Fujikawa H, et al. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Ann Oncol. 2016; 27(10): 1879-86. https://doi.org/10.1093/annonc/mdw279.
45. Ahmed EK, Fahmy SA, Effat H, et al. Circulating MiR-210 and MiR-1246 as Potential Biomarkers for Differentiating Hepatocellular Carcinoma from Metastatic Tumors in the Liver. J Med Biochem. 2019; 38(2): 109-17. https://doi.org/10.2478/jomb-2018-0010.
46. Renesto P, Balloy V, Vargaftig BB, et al. Interference of anti-inflammatory and anti-asthmatic drugs with neutrophil-mediated platelet activation: singularity of azelastine. Br J Pharmacol. 1991; 103(2): 1435-40. https://doi.org/10.1111/j.1476-5381.1991.tb09807.x.
47. Li L, Wang X, Li W, et al. miR-21 modulates prostaglandin signaling and promotes gastric tumorigenesis by targeting 15-PGDH. Biochem Biophys Res Commun. 2018; 495(1): 928-34. https://doi.org/10.1016/j.bbrc.2017.09.137.
48. Самсонов Р.Б., Чебуркин Ю.В., Смирнова А.В. и др. Анализ циркулирующих экзосом - новый метод ранней и дифференциальной диагностики рака поджелудочной железы. Российский биотерапевтический журнал. 2017; 16(s1):69-70].
49. Agaoglu FY, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011; 32(3): 583-588. https://doi.org/10.1007/s13277-011-0154-9.
50. Mohammadi Torbati P, Asadi F, Fard-Esfahani P. Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer. Asian Pac J Cancer Prev. 2019; 20(5): 1453-6. https://doi.org/10.31557/APJCP.2019.20.5.1453.
51. Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016; 15(1): 48. https://doi.org/10.1186/s12943-016-0536-0.
52. Петрова Т.А., Кондратов К.А., Федоров А.В. и др. Изменение уровней циркулирующих микроРНК при патогенезе генетически обусловленного сахарного диабета взрослых у молодых. Трансляционная медицина. 2016; 3(6): 15-20. https://doi.org/10.18705/2311-4495-2016-3-6-15-20.
53. Худяков А.А., Смолина Н.А., Перепелина К.И. и др. Внеклеточные микроРНК и митохондриальная ДНК как потенциальные биомаркеры аритмогенной кардиомиопатии. Биохимия. 2019; 84(3), 392-403. https://doi.org/10.1134/S0320972519030096.
54. Polyakova EA, Zaraiskii MI, Mikhaylov EN, et al. Association of myocardial and serum miRNA expression patterns with the presence and extent of coronary artery disease: A cross-sectional study. Int J Cardiol. 2021; 322: 9-15. https://doi.org/10.1016/j.ijcard.2020.08.043.
55. Zhu W, Liu M, Fan Y, et al. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. Cancer Med. 2018; 7(9): 4420-33. https://doi.org/10.1002/cam4.1723.
56. Papadaki C, Stratigos M, Markakis G, et al. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Res. 2018; 20(1): 72. https://doi.org/10.1186/s13058-018-1001-3.
57. Heitzer E, Haque IS, Roberts CES, et al. Current and future perspectives of liquid biopsies in genomicsdriven oncology. Nat Rev Genet. 2019; 20(2): 71-88. https://doi.org/10.1038/s41576-018-0071-5.
58. Ye Q, Ling S, Zheng S, et al. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019; 18(1): 114. https://doi.org/10.1186/s12943-019-1043-x.
59. Самсонов Р.Б., Бурдаков В.С., Штам Т.А. и др. Метод дифференциальной диагностики узловых заболеваний щитовидной железы: анализ комбинации микроРНК (миРНК-21, -181a и -146а). Опухоли головы и шеи. 2017; 7(2): 16-24. https://doi.org/10.17650/2222-1468-2017-7-2-16-24.
60. Iwamoto H, Kanda Y, Sejima T, et al. Serum miR210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014; 44(1): 53-58. https://doi.org/10.3892/ijo.2013.2169.
61. Bo HQ, Ma X, Zhang X, et al. Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4. PloS One. 2013; 8(6): e67294. https://doi.org/10.1371/journal.pone.0067294.
62. Szabo Z, Szegedi K, Gombos K, et al. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC. Urol Oncol. 2016; 34(12): 533. e21-533.e27. https://doi.org/10.1016/j.urolonc.2016.06.011.
63. Wu X, Weng L, Li X, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 2012; 7(5): e35661. https://doi.org/10.1371/journal.pone.0035661.
64. Wang X, Wang T, Chen C, et al. Serum exosomal miR-210 as a potential biomarker for clear cell renal cell carcinoma. J Cell Biochem. 2019; 120(2): 1492-1502. https://doi.org/10.1002/jcb.27347.
65. Petrozza V, Pastore AL, Palleschi G, et al. Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma. Oncotarget. 2017; 8(41): 69551-69558. https://doi.org/10.18632/oncotarget.18449.
66. Petrozza V, Costantini M, Tito C, et al. Emerging role of secreted miR-210-3p as potential biomarker for clear cell renal cell carcinoma metastasis. Cancer Biomark. 2020; 27(2): 181-188. https://doi.org/10.3233/CBM190242.
67. Li G, Zhao A, Peoch M, et al. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma. Urol Oncol. 2017; 35(5): 294-299. https://doi.org/10.1016/j.urolonc.2016.12.007.
68. Di Meo A, Brown MD, Finelli A, et al. Prognostic urinary miRNAs for the assessment of small renal masses. Clin Biochem. 2020; 75: 15-22. https://doi.org/10.1016/j.clinbiochem.2019.10.002.
69. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10): 997-1006. https://doi.org/10.1038/cr.2008.282.
70. Shi L, Wang M, Li H, et al. MicroRNAs in Body Fluids: A More Promising Biomarker for Clear Cell Renal Cell Carcinoma. Cancer Manag Res. 2021; 13: 7663-7675. https://doi.org/10.2147/CMAR.S330881.
71. Wang K, Yuan Y, Cho JH, et al. Comparing the MicroRNA spectrum between serum and plasma. PLoS One. 2012; 7(7): e41561. https://doi.org/10.1371/journal.pone.0041561.
72. Chanudet E, Wozniak MB, Bouaoun L, et al. Large-scale genome-wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late-stage disease. Int J Cancer. 2017; 141(9): 1730-1740. https://doi.org/10.1002/ijc.30845.
73. Lou N, Ruan AM, Qiu B, et al. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol. 2017; 35(1): 36.e7-36.e14. https://doi.org/10.1016/j.urolonc.2016.07.012.
74. Huang G, Li H, Wang J, et al. Combination of tumor suppressor miR-20b-5p, miR-30a-5p, and miR196a-5p as a serum diagnostic panel for renal cell carcinoma. Pathol Res Pract. 2020; 216(11): 153152. https://doi.org/10.1016/j.prp.2020.153152.
75. Штам Т.А., Самсонов Р.Б., Волницкий А.В. и др. Сравнительный анализ методов выделения внеклеточных микровезикул из культуральной среды. Биомедицинская химия. 2018; 64(1): 23-30. https://doi.org/10.18097/PBMC20186401023.
76. Малек А.В., Берштейн Л.М., Филатов М.В. и др. Система экзосомальных межклеточных коммуникаций и ее роль в процессе метастатической диссеминации. Вопросы онкологии. 2014; 60(4): 429-436]. PMID: 25552061.
77. Rana S, Malinowska K, Zöller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 2013; 15(3): 281-295. https://doi.org/10.1593/neo.122010.
78. Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol. 2011; 2011: 842-849. https://doi.org/10.1155/2011/842849.
79. Butz H, Nofech-Mozes R, Ding Q, et al. Exosomal MicroRNAs are diagnostic biomarkers and can mediate cell-cell communication in renal cell carcinoma. Eur Urol Focus. 2016; 2(2): 210-218. https://doi.org/10.1016/j.euf.2015.11.006.
80. Crentsil VC, Liu H, Sellitti DF. Comparison of exosomal microRNAs secreted by 786-O clear cell renal carcinoma cells and HK-2 proximal tubule-derived cells in culture identifies microRNA-205 as a potential biomarker of clear cell renal carcinoma. Oncol Lett. 2018; 16(1): 1285-1290. https://doi.org/10.3892/ol.2018.8751.
81. Самсонов Р.Б., Чебуркин Ю.В., Штам Т.А., Малек А.В. Анализ биохимического состава циркулирующих экзосом - метод первичной и дифференциальной диагностики онкологических заболеваний. Биотехнология: состояние и перспективы развития - материалы IX Международного Конгресса. 20-22 февраля 2017; Том 1. Издательство: ООО «Русские Экспо Дни Групп» (Москва)]. ISBN: 978-5-9909118-0-2.
82. Zhao L, Liu K, Pan X, et al. miR-625-3p promotes migration and invasion and reduces apoptosis of clear cell renal cell carcinoma. Am J Transl Res. 2019; 11(10): 6475-6486. PMID: 31737199.
83. Pigati L, Yaddanapudi SCS, Iyengar R, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010; 5(10): e13515. https://doi.org/10.1371/journal.pone.0013515.
84. Tang K, Xu H. Prognostic value of metasignature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysis. Sci Rep. 2015; 5: 10272. https://doi.org/10.1038/srep10272.
85. Song F, Yang D, Liu B, et al. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin. Cancer Res. 2014; 20(4): 878-889. https://doi.org/10.1158/1078-0432.CCR-13-1844.
86. Dhayat SA, Mardin WA, Köhler G, et al. The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma? J. Surg. Oncol. 2014; 110(4): 430-438. https://doi.org/10.1002/jso.23668.
87. Cheng G, Li M, Ma X, et al. Systematic analysis of microRNA biomarkers for diagnosis, prognosis, and therapy in patients with clear cell renal cell carcinoma. Front Oncol. 2020; 10: 543817. https://doi.org/10.3389/fonc.2020.543817.
88. Fan Y, Ma X, Li H, et al. miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating Dicer. Int J Cancer. 2017; 142(3): 547-560. https://doi.org/10.1002/ijc.31050.
89. Tusong H, Maolakuerban N, Guan J, et al. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma. Cancer Biomark. 2017; 18(1): 79-85. https://doi.org/10.3233/CBM-160676.
90. Heinemann FG, Tolkach Y, Deng M, et al. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics. 2018; 10:11. https://doi.org/10.1186/s13148-018-0444-9.
91. Liu S, Deng X, Zhang J. Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma. Mol Med Rep. 2019; 20(6): 5075-5083. https://doi.org/10.3892/mmr.2019.10762.
92. Wang XG, Zhu YW, Wang T, et al. MiR-483-5p downregulation contributed to cell proliferation, metastasis, and inflammation of clear cell renal cell carcinoma. Kaohsiung J Med Sci. 2021; 37(3): 192-199. https://doi.org/10.1002/kjm2.12320.
93. Zhao L, Liu K, Pan X, et al. miR-625-3p promotes migration and invasion and reduces apoptosis of clear cell renal cell carcinoma. Am J Transl Res. 2019; 11(10):6475-6486. PMID: 31737199.
94. Xiao W, Wang C, Chen K, et al. MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. EBioMedicine. 2020; 51: 102622. https://doi.org/10.1016/j.ebiom.2019.102622.
95. Song S, Long M, Yu G, et al. Urinary exosome miR-30c-5p as a biomarker of clear cell renal cell carcinoma that inhibits progression by targeting HSPA5. J Cell Mol Med. 2019; 23(10): 6755-6765. https://doi.org/10.1111/jcmm.14553.
96. Wang L, Yang G, Zhao D, et al. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p. Mol Cancer. 2019; 18(1): 86. https://doi.org/10.1186/s12943-019-0997-z.
97. Xiao CT, Lai WJ, Zhu WA, et al. MicroRNA derived from circulating exosomes as noninvasive biomarkers for diagnosing renal cell carcinoma. Onco Targets Ther. 2020; 13: 10765-10774. https://doi.org/10.2147/OTT.S271606.
98. Chen B, Duan L, Yin G, et al. Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells - Cdc2 activity is up-regulated by targeting WEE1. Clinics (Sao Paulo). 2013; 68(6): 825-833. https://doi.org/10.6061/clinics/2013(06)17.
99. He Y, Liu J, Wang Y, et al. Role of miR-486-5p in regulating renal cell carcinoma cell proliferation and apoptosis via TGF-beta-activated kinase 1. J Cell Biochem. 2019; 120(3): 2954-2963. https://doi.org/10.1002/jcb.26900.
100. Ralla B, Busch J, Florcken A, et al. miR-9-5p in nephrectomy specimens is a potential predictor of primary resistance to first-line treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Cancers (Basel). 2018; 10(9): 321. https://doi.org/10.3390/cancers10090321.
101. Silva-Santos RM, Costa-Pinheiro P, Luis A, et al. MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer. 2013; 109(10): 2646-2653. https://doi.org/10.1038/bjc.2013.552.
102. Hell MP, Thoma CR, Fankhauser N, et al. miR-28-5p promotes chromosomal instability in VHL-associated cancers by inhibiting Mad2 translation. Cancer Res. 2014; 74(9): 2432-2443. https://doi.org/10.1158/0008-5472.CAN13-2041.
103. Nie W, Ni D, Ma X, et al. miR 122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3. Int J Oncol. 2019; 54(2): 559-571. https://doi.org/10.3892/ijo.2018.4636.
104. Chen X, Lou N, Ruan A, et al. miR-224/miR141 ratio as a novel diagnostic biomarker in renal cell carcinoma. Oncol Lett. 2018; 16(2): 1666-1674. https://doi.org/10.3892/ol.2018.8874.
105. Liep J, Kilic E, Meyer HA, et al. Cooperative effect of miR-141-3p and miR-145-5p in the regulation of targets in clear cell renal cell carcinoma. PLoS One. 2016; 11(6): e0157801. https://doi.org/10.1371/journal.pone.0157801.
106. Liu W, Chen H, Wong N, et al. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. Cancer Lett. 2017; 394: 65-75. https://doi.org/10.1016/j.canlet.2017.02.025.
107. Lin C, Li Z, Chen P, et al. Oncogene miR-154-5p regulates cellular function and acts as a molecular marker with poor prognosis in renal cell carcinoma. Life Sci. 2018; 209: 481-489. https://doi.org/10.1016/j.lfs.2018.08.044.
108. Zhang J, Ye Y, Chang DW, et al. Global and targeted miRNA expression profiling in clear cell renal cell carcinoma tissues potentially links miR-155-5p and miR-210-3p to both tumorigenesis and recurrence. Am J Pathol. 2018; 188(11): 2487-2496. https://doi.org/10.1016/j.ajpath.2018.07.026.
109. Ma X, Shen D, Li H, et al. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. Urol Oncol. 2015; 33(4): 169 e161-111. https://doi.org/10.1016/j.urolonc.2015.01.003.
110. Lu GJ, Dong YQ, Zhang QM, et al. miRNA-221 promotes proliferation, migration and invasion by targeting TIMP2 in renal cell carcinoma. Int J Clin Exp Pathol. 2015; 8(5): 5224-5229. PMID: 26191221.
111. Федоров А.В., Минасян С.М., Костарева А.А. и др. Повышение уровня микроРНК-208а в цельной крови после ишемии-реперфузии миокарда у крыс. Регионарное кровообращение и микроциркуляция. 2012; 11(2): 66-71]. https://doi.org/10.24884/1682-6655-2012-11-2-66-71.
Рецензия
Для цитирования:
Бондаренко А.Б., Князева А.Р., Чебуркин Ю.В. Роль микроРНК в диагностике рака почки. Российский журнал персонализированной медицины. 2023;3(5):46-59. https://doi.org/10.18705/2782-3806-2023-3-5-46-59. EDN: BAXAQW
For citation:
Bondarenko A.B., Knyazeva A.R., Cheburkin Yu.V. Role of microRNAs in renal cancer diagnostics. Russian Journal for Personalized Medicine. 2023;3(5):46-59. (In Russ.) https://doi.org/10.18705/2782-3806-2023-3-5-46-59. EDN: BAXAQW
Просмотров:
275
ISSN 2782-3806 (Print)
ISSN 2782-3814 (Online)
ISSN 2782-3814 (Online)
Послать статью по эл. почте 